Qiagen QuantiFERON Monitor for tracking immune function in solid organ transplant patients
Qiagen has announced the QuantiFERON Monitor (QFM), a novel diagnostic for monitoring immune function. It is available in non-European markets for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation.
The product measures the cell-mediated immune response and can provide information on the strength of the immune system in the immunosuppressed solid organ transplant population. It thereby targets an important medical need of physicians who need to assess patients’ risk for both organ rejection and infections in order to determine the right dosage of immunosuppressive drugs.
The test uses a combination of stimulants that specifically target different cell types involved in both the innate and adaptive immune systems to detect cell-mediated immune response, providing qualitative and quantitative measurement of cell-mediated immune function. Results are available the next day, and the dual stimulation with innate and adaptive ligands is said to confer a significant advantage over single-stimulant assays.
The product has the potential to allow clinicians to guide preventative treatment decisions by accurately predicting the risks for organ rejection and infections, as well as reduce the dosing of costly and potentially toxic drugs during recovery. It also holds the potential for application in monitoring immune response for other conditions, including inflammatory bowel disease, HIV, cancer and immunotherapy.
Phone: 03 9840 9800
The Jet Ball by Phenosys is a novel virtual reality experimental system based on an air...
The Illumina Nextera Flex for Enrichment is a targeted sequencing solution.
CerePlex Exilis from Blackrock Microsystems is a lightweight, wireless digital head stage that...